American Society of Retina Specialists

Real-world patients showed improvement in visual acuity and anatomic parameters, but are still at an early time point in TRUCKEE study.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

The best overall outcomes were attained in eyes without fluid and ellipsoid zone integrity preservation, investigators said.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.

A retina care team highlighted positive patient feedback from their makeshift system; could it be a long-term solution?

A greater rate of intravitreal injection appointments were delayed last year, causing worse patient scores in BCVA and OTC.

New cohort analyses show endophthalmitis was not significantly reduced in treatment encounters where both physicians and patients were masked.

Findings from YOSEMITE and RHINE show a significant rate of patients on faricimab were able to extend their dosing to once every 16 weeks after a year of therapy.

Positive phase 1 and 2 findings support an ongoing efficacy assessment of the Ref-1 inhibitor for diabetic retinopathy and diabetic macular edema.

A new cross-sectional analysis from ASRS 2021 show White patients are generally overrepresented in randomized, controlled trials for DME.

Josh Mali, MD, of The Eyes Associates, joins HCPLive to review the key news and developments coming out of the American Society of Retina Specialists 2021 Scientific Meeting.

A cohort assessment of the IRIS registry database shows about 1 in 10 patients to receive anti-VEGF and/or panretinal photocoagulation discontinue therapy for at least 1 year.

There has been controversy over the efficacy and safety of step-therapy for neovascular age-related macular degeneration.

No serious adverse events reported through 24 weeks of a 52 week trial.

Combining the dexamethasone implant with anti-VEGF treatment can restore foveal anatomy in eyes resistant to anti-VEGF injection.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

In a phase 1b study presented virtually during ASRS 2020, investigators found a reduction in central subfield thickness after 12 weeks of OPT-302 combined with aflibercept injections.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

The mean number of injections in the studies over 12 months was 9.36 ± 2.66, with a mean change in ETDRS letters was 7.86 ± 1.37.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.